Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:Q86TM3 (
cage
)
29,987
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Rats were exposed to short-term restraint (held by the tail for 1 min), injected s.c. with saline or subjected to the combination of these treatments. Fifteen and 30 min after these treatments the means serum corticosterone level was significantly increased by more than four times, compared to rats taken directly from their home cages, indicating a stress response. In the peri-aqueductal grey, the level of substance P-like immunoreactivity was increased by 45% (P < 0.01) and 65% (P < 0.01) 30 and 60 min after the combined treatment, respectively. Significant increases of the level of substance P-like immunoreactivity in the peri-aqueductal grey were also found after restraint only and after a s.c. saline injection. Similar, but less marked, changes in the level of
cholecystokinin
-like immunoreactivity in the PAG were also seen. In the accumbens a significantly decreased level of substance P-like immunoreactivity was encountered at 15 and 30 min after treatment, while the levels of
cholecystokinin
- and neuropeptide Y-like immunoreactivity were not significantly changed. In other regions studied, no effects on peptide levels were seen. The changes in peptide levels had a time course similar to that of the increase in serum corticosterone. Also the successive removal of rats from a common
cage
was found to increase significantly the serum corticosterone and the substance P-like immunoreactivity in the peri-aqueductal grey in the animals that were taken late in sequence from the
cage
.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Short-term restraint stress and s.c. saline injection alter the tissue levels of substance P and cholecystokinin in the peri-aqueductal grey and limbic regions of rat brain. 128 65
The effects of neuropeptide Y (NPY), sigma ligand (JO 1784) and sulfated
cholecystokinin
octapeptide (CCK8s) on emotional stress (ES) and corticotropin-releasing hormone (CRH)-induced colonic hypermotility were evaluated in rats equipped with chronically implanted electrodes on the colon and a small catheter into the lateral ventricle of the brain. A 139% (97-172%) increase in colonic spike burst frequency was observed in rats placed in a test
cage
in which they had previously received electric footshocks, an event assimilated to an ES. Intracerebroventricular injection of CRH (0.5 microgram/kg) mimicked the effects of ES by increasing colonic spike burst frequency by 89.0%. Given i.c.v., both JO 1784 (0.1 microgram/kg) and NPY (0.15 microgram/kg) blocked these stimulatory effects. Similarly, i.c.v. administration of CCK8s (0.1 microgram/kg) abolished both ES and CRH stimulated colonic motility, an effect reproduced by central injection of JMV 180, a
cholecystokinin
(
CCK
) derivative with high affinity for CCKA receptors, (1 microgram/kg), but not by JMV 170, a
CCK
derivative with low affinity for CCKA receptor at similar or higher dose. BMY 14802 (a sigma receptor antagonist) injected s.c. (1 mg/kg) abolished the antagonistic effects of JO 1784 and NPY on the ES-induced colonic hyperkinesia. Injected i.c.v., devazepide (L 364,718), a CCKA receptor antagonist, at 0.1 and 1 microgram/kg, abolished the effect of both JO 1784 and NPY; by contrast L365,260, a CCKB antagonist, required a dose of 10 micrograms/kg to block the antagonistic effect of NPY and JO 1784.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Neuropeptide Y and sigma ligand (JO 1784) suppress stress-induced colonic motor disturbances in rats through sigma and cholecystokinin receptors. 131 76
Rats with high and low exploratory activity in an elevated plus-maze model of anxiety were separated into subgroups termed 'non-anxious' and 'anxious' respectively according to the number of sectors the animals crossed and the total amount of time they spent in the open part of the plus-maze. The binding parameters of benzodiazepine and
cholecystokinin
octapeptide (CCK-8) receptors in frontal cortex and hippocampus of selected animals were studied and compared to an animal group representing the total mean scores and to home-
cage
controls. It was established that anxious rats had a significantly lower number of benzodiazepine receptors in frontal cortex as compared to non-anxious animals and in hippocampus as compared to home-
cage
controls. There was also a decreased number of CCK-8 receptors in hippocampus of anxious rats as compared to the non-anxious and control groups. Non-anxious animals had a significantly lower number of CCK-8 receptors in frontal cortex than anxious and control rats. Acute treatment of rats with anxiogenic benzodiazepine inverse agonist FG 7142 (10 and 20 mg/kg) did not influence benzodiazepine binding in brain regions under investigation but caused upregulation of CCK-8 receptor binding in frontal cortex. On the other hand, CCK-8 analogues caerulein and pentagastrin, administered in doses which inhibit exploratory activity in plus-maze (100 or 500 ng/kg respectively), decreased the number of benzodiazepine binding sites in rat frontal cortex if injected intraperitoneally but did not affect CCK-8 binding. The present findings indicate that benzodiazepine and CCK-8 receptor binding characteristics in brain undergo rapid and behaviourally specific changes during stressful events.
...
PMID:Rats with anxious or non-anxious type of exploratory behaviour differ in their brain CCK-8 and benzodiazepine receptor characteristics. 216 92
Haloperidol in low doses antagonized the apomorphine-induced
cage
-climbing behaviour of mice, whereas ceruletide (CER) and its analogue, Nle8-CER-(4-10) had very weak anticlimbing efficacy; Nle8-CER and diazepam were inactive. The ptosis caused by CER and
cholecystokinin
octapeptide (CCK-8) was antagonized by apomorphine in doses 27 times smaller than those effective against the haloperidol-induced ptosis. No such differences occurred when either methylphenidate or picrotoxin replaced apomorphine. Low-dose haloperidol was an antagonist to the antiptotic effect of apomorphine versus both CER and CCK-8. The rearing inhibiting effect of CER and haloperidol, in contrast to that of clonazepam, was very resistant to apomorphine. Methylphenidate was weakly effective against clonazepam and haloperidol but inactive versus CER. Picrotoxin was no antagonist to either rearing inhibiting agent. The results taken together suggest presynaptic sites of the dopaminergic system as important for the production of ptosis by CCK-like peptides.
...
PMID:Neuroleptic-like effects of ceruletide and cholecystokinin octapeptide: interactions with apomorphine, methylphenidate and picrotoxin. 614 Jan 74
The effects of sulfated (CCK-8-SE) and non-sulfated (CCK-8-NS)
cholecystokinin
octapeptide on striatal dopamine (DA) metabolism have been investigated on mice. CCK-8-NS facilitated the disappearance of striatal DA, measured after synthesis inhibition with 350 mg/kg of alpha-methyl-p-tyrosine. CCK-8-SE did not affect DA disappearance. In vitro uptake of [3H]DA by striatal slices was affected by neither CCK-8-SE, nor CCK-8-NS (10(-5) M). Potassium-induced in vitro release of [3H]DA from striatal slices was significantly increased by 10(-5) M CCK-8-NS: however, CCK-8-SE likewise increased DA release in this model system. Apomorphine-induced (1.0 mg/kg) stereotyped
cage
-climbing behavior was not affected by CCK-8-SE but was enhanced by CCK-8-NS. This effect could be antagonized by haloperidol, but not by naloxone. The data suggest that CCK-8-NS affects striatal DA release, disappearance and receptor sensitivity in the mouse. Dopaminergic mechanisms should therefore be regarded as a possible mode of action of CCK-8-NS on brain functions.
...
PMID:Effects of cholecystokinin octapeptide on striatal dopamine metabolism and on apomorphine-induced stereotyped cage-climbing in mice. 626 May 12
Cholecystokinin
(
CCK
) is co-localized with dopamine (DA) in the nucleus accumbens (NAC) where evidence suggests that
CCK
(B) receptor-mediated mechanisms inhibit, while
CCK
(A) receptor-mediated mechanisms facilitate, DA function. As DA has been implicated in the acquisition of conditioned activity, the present experiments investigated the effects of
CCK
(A) and
CCK
(B) receptor selective antagonists on the acquisition and expression of conditioned activity produced by cocaine. Paired rats received four cocaine-environment pairings whereas Unpaired rats received the two stimuli explicitly unpaired, in that they received cocaine in the home
cage
. Using this procedure, cocaine (10 mg/kg, i.p.) reliably produced conditioned activity such that the Paired group showed a higher level of locomotion than the Unpaired group on a subsequent drug-free test day. Systemic administration of devazepide, a
CCK
(A) receptor antagonist, but not L-365,260, a
CCK
(B) receptor antagonist, blocked the acquisition of conditioned activity. Microinjection of the
CCK
(A) antagonist PD-140548 into the NAC similarly impaired the acquisition of conditioned activity. However, systemic administration of neither the
CCK
(A) nor
CCK
(B) receptor antagonist modified the expression of cocaine-induced conditioned activity once established. These studies suggest that
CCK
(A), but not
CCK
(B), receptor mediated mechanisms in the NAC play a key role in the acquisition of conditioned activity.
...
PMID:Evidence for CCK(A) receptor involvement in the acquisition of conditioned activity produced by cocaine in rats. 927 33
To investigate
cholecystokinin
(
CCK
) mRNA changes induced by social isolation rats were isolated in single cages soon after weaning for 30 days. They were then sacrificed and their brains removed for in situ hybridization (ISH) study. Control animals were housed in groups of 6 per
cage
for the same period. ISH was performed using a 32P-labelled oligonucleotide probe complementary to
CCK
-8 mRNA and the results analysed by computerized densitometry. They showed a significant increase (from 59.5-152.3%) in
CCK
mRNA expression in the basolateral amygdala, cortex, CA1, dorsal raphe nucleus, geniculate body and ventral tegmental area of isolated rats. These results suggest that social isolation may influence
CCK
gene expression.
...
PMID:Social isolation increases cholecystokinin mRNA in the central nervous system of rats. 942 33
Forty-five male Wistar rats were selected according to their behavior in the elevated plus-maze. They were separated as follows: animals with low exploratory activity ('anxious'), an 'intermediate' group and animals having high exploratory activity ('non-anxious'). Various receptor binding studies and hormonal assays were also performed in these selected rats. The affinity of 5-hydroxytryptamine 5-HT2A receptors in the frontal cortex was lower in the 'anxious' rats compared to home-
cage
controls and 'non-anxious' animals. Moreover, the number of
cholecystokinin
(
CCK
) receptors in the hippocampus was significantly elevated in the 'anxious' group compared to home-
cage
control animals. The blood levels of growth hormone (GH) were significantly lower in the 'non-anxious' rats compared to 'anxious' counterparts. In conclusion, it seems likely that the decreased exploratory activity of rats is related to the increased 5-hydroxytryptamine (5-HT) and
CCK
mediated neurotransmission in the brain. The different serum levels of GH in the selected rats probably reflect alterations in the activity of 5-HT and
CCK
.
...
PMID:Relation of exploratory behavior of rats in elevated plus-maze to brain receptor binding properties and serum growth hormone levels. 944 61
Exposure of guinea pigs to the elevated plus maze (X-maze), an animal model of anxiety, causes an increase of extracellular serotonin (5-HT) in the lateral prefrontal cortex monitored by microdialysis. The neuropeptide
cholecystokinin
(
CCK
) plays a role in the modulation of anxiety. To compare the roles of
CCK
receptors, the effects of the CCK-A receptor agonist A-71378, the CCK-A/B receptor agonist
CCK
-8S and the CCK-B receptor agonist BOC-CCK-4 on anxiety-related behavior and the 5-HT release in the prefrontal cortex were determined. None of the drugs changed the behavior of the guinea pigs and the cortical 5-HT release under resting conditions in the familiar home
cage
. A-71378 and
CCK
-8S had no effect on the behavior on exposure to the X-maze whereas BOC-CCK-4 induced an 'anxious' behavior. The results suggest that 'anxious' behavior induced by
CCK
is associated with selective CCK-B receptor stimulation. A-71378 inhibited the rise in 5-HT on exposure to the X-maze.
CCK
-8S had no effect and the anxiogenic BOC-CCK-4 potentiated the rise in 5-HT on the X-maze. Both
CCK
receptors mediate changes in 5-HT release under aversive conditions, but not in a resting state. The results suggest a receptor subtype-specific influence of
CCK
on behavior and 5-HT activity under aversive conditions.
...
PMID:Effects of cholecystokinin-receptor agonists on cortical 5-HT release in guinea pigs on the X-maze. 953 40
Cholecystokinin
(
CCK
) can have effects opposite those of opioids. The present study was undertaken to determine whether peripheral injections of antagonists of the CCK1 receptor (lorglumide) and the CCK2 receptor (L-365,260) can influence the effects of morphine on maternal behavior during lactation. A total of 110 female Wistar rats were tested on days 5 and 6 postpartum. Groups were randomly assigned to morphine vehicle (MV-SC) + saline (S-IP), MV + lorglumide (LOR: 1.0 or 10.0 mg/kg), MV + L-365,260 (10 mg/kg), morphine chlorhydrate (MC: 7.0 mg/kg) + S, MC + LOR (1.0 or 10.0 mg/kg), and MC + L-365,260 (1.0 or 10 mg/kg). Maternal behavior testing was started 30 min after the injections, at which time pups were placed in the home
cage
of their mother. Latencies for retrieval, grouping, and crouching responses were scored. The results show that both lorglumide and L-365,260 potentiated the MC-induced inhibition of maternal behavior. In addition L-365,260 treatment alone inhibited maternal behavior. Blockade of both the CCK1 and CCK2 receptors potentiated the morphine-induced disruption of maternal behavior, while CCK2 antagonism alone also inhibited this behavior. The results suggest that
CCK
antagonism of opioid-induced disruption of maternal behavior occurs due to the action of
CCK
on both CCK1 and CCK2 receptor subtypes.
...
PMID:Differential role of cholecystokinin receptor subtypes in opioid modulation of ongoing maternal behavior. 1049 12
1
2
Next >>